Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Medicine, Oncology,
tumor mutational burden   immune checkpoint inhibition   metastatic melanoma   real-world study   biomarkers   efficacy prediction   BRAF status  

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...

Tumor-Associated NK Cells Drive MDSC-Mediated Tumor Immune Tolerance Through the IL-6/STAT3 Axis

Medicine, Oncology, Life Sciences, Immunology,
NK cells   MDSC   tumor immune escape   IL-6   STAT3   antigen presentation   immune checkpoint inhibition  

Tumor-Associated NK Cells Drive MDSC-Mediated Tumor Immune Tolerance via the IL-6/STAT3 Axis — Research by Neo et al. In recent years, researchers have delved deeply into the mechanisms of tumor immune escape to improve the success rate of cancer immunotherapy. The accumulation of CD8 T cells in the tumor microenvironment is a critical determinant ...